Compare DRUG & SLRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DRUG | SLRC |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.1M | 803.0M |
| IPO Year | 2020 | 2007 |
| Metric | DRUG | SLRC |
|---|---|---|
| Price | $61.24 | $12.63 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 7 |
| Target Price | ★ $129.25 | $15.14 |
| AVG Volume (30 Days) | ★ 396.0K | 291.3K |
| Earning Date | 05-15-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 10.49% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.31 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $41.68 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.18 | $12.54 |
| 52 Week High | $123.75 | $16.75 |
| Indicator | DRUG | SLRC |
|---|---|---|
| Relative Strength Index (RSI) | 28.07 | 35.50 |
| Support Level | $49.47 | N/A |
| Resistance Level | $61.76 | $15.52 |
| Average True Range (ATR) | 5.33 | 0.23 |
| MACD | -2.13 | 0.04 |
| Stochastic Oscillator | 5.52 | 13.64 |
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. The company's investment objective is to generate both current income and capital appreciation through debt and equity investments. The company invests principally in leveraged middle-market companies in the form of senior secured loans, financing leases, and to a lesser extent, unsecured loans and equity securities.